Self-determinism: alloBMT for AML.

In this issue of Blood , Kurosawa et al use a Markov decision process (MDP) of allogeneic hematopoietic cell transplantation (alloHCT) versus chemotherapy in patients with acute myeloid leukemia (AML) in first complete remission (CR1).[1][1] “In probability theory, a stochastic or random process

[1]  J. Doob.  Stochastic processes , 1953 .

[2]  John P Klein,et al.  A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. , 2004, Blood.

[3]  John P Klein,et al.  Regression Modeling of Competing Risks Data Based on Pseudovalues of the Cumulative Incidence Function , 2005, Biometrics.

[4]  M. Weinstein,et al.  Unrelated Donor Bone Marrow Transplantation for Chronic Myelogenous Leukemia: A Decision Analysis , 1997, Annals of Internal Medicine.

[5]  Y. Kanda,et al.  A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. , 2011, Blood.

[6]  E R Carson,et al.  Dynamic decision models for clinical diagnosis. , 1976, International journal of bio-medical computing.

[7]  G. Skrepnek,et al.  Cost‐Efficacy of Imatinib versus Allogeneic Bone Marrow Transplantation with a Matched Unrelated Donor in the Treatment of Chronic Myelogenous Leukemia: A Decision‐Analytic Approach , 2005, Pharmacotherapy.

[8]  H. Heimpel,et al.  Allogenic bone marrow transplantation of chemotherapy for patients with acute myeloid leukemia in first complete remission: a decision analysis approach , 1996, Annals of Hematology.

[9]  Matthijs T. J. Spaan,et al.  Partially Observable Markov Decision Processes , 2010, Encyclopedia of Machine Learning.

[10]  Hein Putter,et al.  Dynamic predicting by landmarking as an alternative for multi-state modeling: an application to acute lymphoid leukemia data , 2008, Lifetime data analysis.